Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

Biogen BIIB reported second-quarter 2025 adjusted earnings per share (EPS) of $5.47, which significantly beat the Zacks ...

Biogen (NASDAQ:BIIB) traded ~8% higher in the premarket on Thursday after the company posted better-than-expected financials ...

Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...

In February 2025, Biogen Inc. (NASDAQ:BIIB) formed a partnership with Stoke Therapeutics to develop zorevunersen for Dravet ...

In the preceding three months, 8 analysts have released ratings for Biogen BIIB -0.98% Get Free Report , presenting a wide ...

Looking at the chart above, BIIB's low point in its 52 week range is $194.45 per share, with $319.76 as the 52 week high point — that compares with a last trade of $253.71. Find out what 9 other ...

So BIIB is spinning this business out because it's viable, but holding the bigger company back in the long term. This is more of a graceful exit than a split with mutual benefits.

Biogen Inc. Quarterly stock financials by MarketWatch. View the latest BIIB financial statements, income statements and financial ratios.